Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of repeated intensive chemotherapy in young adults with primary acute lymphoblastic leukemia
ISRCTN78775328Phase 2Completed
- Sponsor
- HOVON
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of prednisone, vincristine, daunorubicin, cyclophosphamide, asparaginase escherichia coli and 8 more in acute lymphoblastic leukemia (ALL), sponsored by HOVON. Primary endpoint: Primary feasibility endpoint. Started Oct 2005; status: completed.
02
Drugs
prednisonevincristinedaunorubicincyclophosphamideasparaginase escherichia coli
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN78775328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78775328.